<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">medRxiv</journal-id><journal-id journal-id-type="pmc-domain-id">3854</journal-id><journal-id journal-id-type="pmc-domain">medrxiv</journal-id><journal-id journal-id-type="publisher-id">MEDRXIV</journal-id><journal-title-group><journal-title>medRxiv</journal-title></journal-title-group><publisher><publisher-name>Cold Spring Harbor Laboratory Preprints</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10854342</article-id><article-id pub-id-type="pmcid-ver">PMC10854342.2</article-id><article-id pub-id-type="pmcaid">10854342</article-id><article-id pub-id-type="pmcaiid">11005648</article-id><article-id pub-id-type="pmid">38343815</article-id><article-id pub-id-type="doi">10.1101/2024.01.24.24301555</article-id><article-version-alternatives><article-version article-version-type="pmc-version">2</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2049-6918</contrib-id><name name-style="western"><surname>Ross</surname><given-names initials="RK">Rachael K.</given-names></name><aff id="A1">Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2055-3425</contrib-id><name name-style="western"><surname>Nunes</surname><given-names initials="EV">Edward V.</given-names></name><aff id="A2">Department of Psychiatry, Columbia University Irving Medical Center</aff><aff id="A3">New York State Psychiatric Institute, New York, NY</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olfson</surname><given-names initials="M">Mark</given-names></name><aff id="A4">Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY</aff><aff id="A5">Department of Psychiatry, Columbia University Irving Medical Center</aff><aff id="A6">New York State Psychiatric Institute, New York, NY</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shulman</surname><given-names initials="M">Matisyahu</given-names></name><aff id="A7">Department of Psychiatry, Columbia University Irving Medical Center</aff><aff id="A8">New York State Psychiatric Institute, New York, NY</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names initials="N">Noa</given-names></name><aff id="A9">Department of Population Health, New York University, New York, NY</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stuart</surname><given-names initials="EA">Elizabeth A.</given-names></name><aff id="A10">Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rudolph</surname><given-names initials="KE">Kara E.</given-names></name><aff id="A11">Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY</aff></contrib></contrib-group><author-notes><corresp id="CR1">Corresponding author: Dr. Rachael Ross, Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY 10032; <email>rachael.k.ross@columbia.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>4</month><year>2024</year></pub-date><issue-id pub-id-type="pmc-issue-id">455572</issue-id><elocation-id>2024.01.24.24301555</elocation-id><pub-history><event event-type="pmc-release"><date><day>10</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-06 17:25:19.050"><day>06</day><month>12</month><year>2024</year></date></event><event event-type="original-publication" specific-use="live"><article-id pub-id-type="pmcaiid">10854342</article-id><article-version>1</article-version><pub-date><day>24</day><month>01</month><year>2024</year></pub-date></event><event event-type="pmc-published-version" specific-use="live"><article-id pub-id-type="pmcaiid">10854342</article-id><article-version>1</article-version><pub-date><day>24</day><month>01</month><year>2024</year></pub-date></event><event event-type="pmc-published-version" specific-use="live"><article-id pub-id-type="pmcaiid">11005648</article-id><article-version>2</article-version><pub-date><day>01</day><month>04</month><year>2024</year></pub-date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</ext-link>, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihpp-2024.01.24.24301555v2.pdf"/><self-uri content-type="pdf">nihpp-2024.01.24.24301555.pdf</self-uri><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="published-article" xml:lang="en" xlink:title="research-article" journal-id="Addiction" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="39099417"><article-title>Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients</article-title><volume>119</volume><issue>11</issue><date><day>5</day><month>8</month><year>2024</year></date><fpage>1975</fpage><lpage>1986</lpage><source>Addiction (Abingdon, England)</source><pub-id pub-id-type="doi">10.1111/add.16630</pub-id><pub-id pub-id-type="pmid">39099417</pub-id></related-article><abstract id="ABS1"><sec id="S1"><title>Aims:</title><p id="P1">To compare the real-world effectiveness of extended release naltrexone (XR-NTX) and sublingual buprenorphine (SL-BUP) for the treatment of opioid use disorder (OUD)</p></sec><sec id="S2"><title>Design:</title><p id="P2">An observational active comparator, new user cohort study</p></sec><sec id="S3"><title>Setting:</title><p id="P3">Medicaid claims records for patients in New Jersey and California, 2016&#8211;2019</p></sec><sec id="S4"><title>Participants/Cases:</title><p id="P4">Adult Medicaid patients aged 18&#8211;64 years who initiated XR-NTX or SL-BUP for maintenance treatment of OUD and did not use medications for OUD in the 90-days before initiation</p></sec><sec id="S5"><title>Comparators:</title><p id="P5">New initiation with XR-NTX versus SL-BUP for the treatment of OUD</p></sec><sec id="S6"><title>Measurements:</title><p id="P6">We examined two outcomes up to 180 days after medication initiation, 1) composite of medication discontinuation and death, and 2) composite of overdose and death</p></sec><sec id="S7"><title>Findings:</title><p id="P7">Our cohort included 1,755 XR-NTX and 9,886 SL-BUP patients. In adjusted analyses, treatment with XR-NTX was more likely to result in discontinuation or death by the end of follow-up than treatment with SL-BUP: cumulative risk 76% (95% confidence interval [CI] 75%, 78%) versus 62% (95% CI 61%, 63%), respectively (risk difference 14 percentage points, 95% CI 13, 16). There was minimal difference in the cumulative risk of overdose or death by the end of follow-up: XR-NTX 3.8% (95% CI 2.9%, 4.7%) versus SL-BUP 3.3% (95% 2.9%, 3.7%); risk difference 0.5 percentage points, 95%CI &#8722;0.5, 1.5. Results were consistent across sensitivity analyses.</p></sec><sec id="S8"><title>Conclusions:</title><p id="P8">Longer medication retention is important because risks of negative outcomes are elevated after discontinuation. Our results support selection of SL-BUP over XR-NTX. However, most patients discontinued medication by 6 months indicating that more effective tools are needed to improve medication retention, particularly after initiation with XR-NTX, and to identify which patients do best on which medication.</p></sec></abstract><kwd-group><kwd>extended release naltrexone</kwd><kwd>sublingual buprenorphine</kwd><kwd>opioid use disorder</kwd><kwd>Medicaid</kwd><kwd>treatment retention</kwd><kwd>overdose</kwd></kwd-group><funding-group><award-group id="award01"><funding-source>NIH NIDA</funding-source><award-id>5R01DA056407</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S9"><title>Introduction</title><p id="P9">In the US, there are three Food and Drug Administration approved medications for opioid use disorder (OUD) treatment. Methadone, a full opioid agonist, can only be provided for the treatment of OUD at federally accredited Opioid Treatment Programs (OTPs). In contrast, buprenorphine (BUP), a partial opioid agonist, and naltrexone (NTX), an opioid antagonist, can be provided for the treatment of OUD in any medical setting. Although NTX is available as a daily oral medication and an extended-release (XR) monthly injection, current OUD guidelines only recommend XR-NTX.[<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>] BUP also has oral (sublingual, SL) and XR formulations, though SL-BUP is by far the most commonly prescribed BUP formulation for OUD.[<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>] Therefore, outside of OTPs, patients and their providers may have a choice between XR-NTX and SL-BUP for the treatment of OUD and more evidence, particularly evidence from usual care settings, is needed on their relative effectiveness.[<xref rid="R2" ref-type="bibr">2</xref>]</p><p id="P10">XR-NTX and SL-BUP for treatment of OUD have previously been compared in randomized clinical trials.[<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>] In these trials there was large variability (range 47%&#8211;89%) in the proportion of participants assigned XR-NTX who successfully initiated treatment. In contrast, most participants (73%&#8211;94%) successfully initiated SL-BUP. Treatment retention was similar between XR-NTX and SL-BUP among those who successfully initiated medication across the trials. Only one trial had sufficient overdose events to compare the medications for this outcome.[<xref rid="R7" ref-type="bibr">7</xref>] Although the original analysis did not report a significant difference in the proportion of overdoses by medication, a reanalysis found that XR-NTX had a higher hazard of overdose than SL-BUP.[<xref rid="R8" ref-type="bibr">8</xref>] Thus, questions remain about the relative protection against overdose provided by these medications.[<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>]</p><p id="P11">Few studies have compared these medications in usual care settings using real-world data. Although randomized clinical trials are the gold-standard in producing evidence of comparative efficacy, there are important reasons to compare these medications using real-world data. Patients enrolled in clinical trials may not be representative of the real-world population of patients with OUD.[<xref rid="R12" ref-type="bibr">12</xref>] How treatment is delivered (e.g., intensity of follow-up, monetary incentives) also differs between trials and real-world practice. These differences in patient characteristics and treatment delivery are likely to modify treatment effectiveness.[<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>] Additionally, real-world data sources tend to provide larger samples sizes, which enables analysis of rare outcomes like overdose. We identified just two studies that compared XR-NTX and SL-BUP initiation using real-world data; one examined treatment retention and the other examined overdose.[<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>] However these studies used data (US commercial claims) from 2010&#8211;2014 and 2010&#8211;2016, respectively; periods that do not capture the rise in fentanyl.[<xref rid="R17" ref-type="bibr">17</xref>] Other studies did not distinguish between XR and oral NTX.[<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>] Therefore, we sought to update real-world evidence on the comparative effectiveness of XR-NTX and SL-BUP. Specifically, we compared the risk of early treatment discontinuation (before 6 months) and the risk of overdose after initiation of XR-NTX or SL-BUP for the treatment of OUD among Medicaid patients in New Jersey (NJ) and California (CA).</p></sec><sec id="S10"><title>Methods</title><sec id="S11"><title>Study design and data source</title><p id="P12">We implemented an active comparator, new user cohort study[<xref rid="R20" ref-type="bibr">20</xref>] using 2016&#8211;2019 Medicaid claims data from CA and NJ (Transformed Medicaid Statistical Information System [T-MSIS] Analytic Files). Both CA and NJ implemented Medicaid expansion in 2014. These data include inpatient and other services claims and outpatient pharmacy dispensing claims for Medicaid enrolled patients. The Columbia University Institutional Review Board approved this study (AAAU3366).</p><p id="P13">We used the target trial emulation framework to inform the study design and analytic decisions.[<xref rid="R21" ref-type="bibr">21</xref>] <xref rid="SD1" ref-type="supplementary-material">Appendix Table 1</xref> outlines the elements of the trial we attempted to emulate using observational data. The new user cohort study emulates a trial that enrolls individuals with OUD who are not currently taking XR-NTX or SL-BUP or any other medication for OUD (MOUD).</p></sec><sec id="S12"><title>Study cohort</title><p id="P14"><xref rid="SD1" ref-type="supplementary-material">Appendix Figure 1</xref> depicts the study cohort design including the time windows used to assess inclusion and exclusion criteria. <xref rid="F1" ref-type="fig">Figure 1</xref> is the flow diagram illustrating cohort assembly. As described in detail below, the cohort included adult Medicaid patients aged 18&#8211;64 years who initiated XR-NTX or SL-BUP for maintenance treatment of OUD, did not have MOUD use in the 90-days before initiation, and had 6-months of continuous enrollment before initiation. We excluded patients who were pregnant, had a cancer diagnosis, or received long-term, palliative, or hospice in the baseline period. We included patients at their first eligible medication initiation and the date of initiation was the date of cohort entry (day 0).</p><sec id="S13"><title>Cohort creation details</title><p id="P15">We first identified patients aged 18&#8211;64 years with a claim for XR-NTX or SL-BUP using 1) a National Drug Code (NDC) on an outpatient pharmacy claim, inpatient claim, or other services claim; or 2) a procedure code (Healthcare Common Procedure Coding System or Current Procedural Terminology) on an inpatient or other services claim (<xref rid="SD1" ref-type="supplementary-material">Appendix Table 2</xref>). Codes were compiled from multiple sources and the literature.[<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>] We refer to this medication claim as the index claim and the date is day 0. A single patient may have multiple claims for XR-NTX or SL-BUP. The exclusion criteria below were applied to each index claim (as a potentially eligible treatment initiation).</p><p id="P16">First, to establish a baseline period, we excluded patients who were not continuously enrolled with full benefits and without dual Medicare coverage in the calendar month of index claim or in the 6 calendar months prior. Second, to restrict to new users, we excluded patients with other MOUD claims (for BUP (any route), XR-NTX, or methadone) on the same day as the index claim or in the 90 days prior. Third, to restrict to new users of maintenance medication, as opposed to medication for medically managed withdrawal, we excluded SL-BUP treatment that was less than 7 days in duration (assessed using claims during days 0 to +14). Because this criterion necessarily required us to use data after day 0, we also excluded patients who were censored (because of loss to follow-up or study period ended) or who had the outcome in the first 14 days to avoid immortal time bias.[<xref rid="R26" ref-type="bibr">26</xref>] Fourth, to restrict to OUD treatment, we excluded patients who did not have an ICD-10 diagnosis code indicating opioid dependence, abuse, or overdose in the 6-month baseline period (defined above). Fifth, we excluded patients who were pregnant on day 0, or who had a cancer diagnosis or received long-term, palliative, or hospice care in the baseline period. Finally, as patients may be eligible for our cohort multiple times in the study period, we restricted to the first eligible medication initiation.</p></sec></sec><sec id="S14"><title>Treatments</title><p id="P17">We compared initiation of XR-NTX to initiation of SL-BUP for the treatment of OUD.</p></sec><sec id="S15"><title>Outcomes</title><p id="P18">We assessed two composite outcomes: 1) medication discontinuation or death, and 2) overdose or death. We divided the period after treatment initiation into weeks, where week 1 was days 1&#8211;7, week 2 was days 8&#8211;14, etc. and we continued follow-up to 180 days (week 26). Outcome measurement started in week 3 (day 15).</p><sec id="S16"><title>Medication discontinuation</title><p id="P19">We examined two definitions for medication discontinuation: 1) discontinued all MOUD (i.e., patients were allowed to switch treatments, including between XR-NTX and SL-BUP or to methadone or XR-BUP) and 2) discontinued initial medication. We considered time during which the patient had access to dispensed or administered medication as continued use. We assumed use began on the day of the medication claim regardless of overlap with prior claims (i.e., we did not allow stockpiling). For XR-NTX, we assumed 30 days of use for each claim. For SL-BUP, we assumed use equaled the days supply for pharmacy fills or 1 day for all other codes. We summed days for multiple SL-BUP claims on the same day. In our first definition of discontinuation, we allowed switching to XR-BUP or methadone. For XR-BUP, we assumed 30 days for injection and 180 days for implant. For methadone, we assumed 1 day except for weekly bundle codes. We summed methadone claims on the same day.</p><p id="P20">We used a 31-day grace period: once medication for a claim was finished, we looked for a subsequent claim for up to 31 days; if there was no claim, the date of discontinuation was the end of the grace period. Prior research[<xref rid="R27" ref-type="bibr">27</xref>] has used a 30-day grace period, however we observed that some claims occurred exactly monthly.</p></sec><sec id="S17"><title>Overdose</title><p id="P21">Given our data source, we only captured overdose that resulted in an insurance claim. We used ICD-10 diagnosis codes on inpatient or other services claims for opioid or unspecified narcotic poisoning (<xref rid="SD1" ref-type="supplementary-material">Appendix Table 2</xref>).[<xref rid="R28" ref-type="bibr">28</xref>]</p></sec><sec id="S18"><title>Death</title><p id="P22">We identified the occurrence and date of death from the demographic and enrollment file. These data captured death during Medicaid enrollment only.</p></sec></sec><sec id="S19"><title>Covariates</title><p id="P23">Demographic factors were assessed during the calendar month of cohort entry: age, gender, race/ethnicity, state, and Temporary Assistance for Needy Families (TANF) benefits. Other baseline covariates (<xref rid="T1" ref-type="table">Table 1</xref>) were assessed in the baseline period (prior to cohort entry). They included OUD characteristics, other substance use disorders, psychiatric comorbid conditions, other comorbid conditions, medicationsand healthcare utilization. Code lists are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/CI-NYC" ext-link-type="uri">https://github.com/CI-NYC</ext-link>.</p></sec><sec id="S20"><title>Primary analysis</title><p id="P24">We aimed to estimate the average treatment effect (ATE), which is the difference in the marginal cumulative risk of the outcome throughout follow-up under two counterfactual scenarios: 1) had everyone in the study cohort initiated XR-NTX, versus 2) had everyone in the study cohort initiated SL-BUP. In the analysis of each composite outcome, we censored patients at the earliest occurrence of 1) the outcome, 2) loss to follow-up, 3) study period end on 12/31/2019, or 4) 180 days (26 weeks). A patient was considered lost to follow-up when the patient disenrolled, no longer had full benefits, or acquired dual coverage.</p><p id="P25">First, we conducted a crude analysis. We used the Kaplan-Meier estimator to estimate the cumulative risk of each outcome by week for each medication and the risk difference between medication groups. Next, we conducted an adjusted analysis that accounted for confounding and potentially informative censoring by standardizing by the covariates described above and calendar year at cohort entry. For the adjusted analysis, we used a sequentially doubly robust estimator (R package lmtp).[<xref rid="R29" ref-type="bibr">29</xref>] This estimator relies on estimating models for treatment conditional on covariates; time-varying censoring conditional on treatment and covariates; and time-varying outcome conditional on treatment and covariates. These models were estimated flexibly using an ensemble of machine learning algorithms that included an intercept-only model, a main-effects logistic model, gradient boosting machines, and multivariate adaptive regression splines.[<xref rid="R30" ref-type="bibr">30</xref>] We estimated the variance using the sample variance of the efficient influence function and constructed Wald-type 95% confidence intervals (CI).[<xref rid="R31" ref-type="bibr">31</xref>] Such an analysis is accurate (i.e., our estimated risk difference can be interpreted as the ATE) when there is no residual bias from confounding or informative censoring (i.e., conditional exchangeability) and all patients (defined by the measured covariates) have the possibility of receiving either medication and of remaining uncensored (i.e., positivity). We used R (v4.3.1; R Core Team 2021).</p></sec><sec id="S21"><title>Additional analyses</title><p id="P26">In our cohort, we observed that patients who initiated XR-NTX were more likely to have alcohol use disorder (AUD) and less likely to have chronic pain than patients who initiated SL-BUP. Given that XR-NTX is also indicated for AUD and BUP is indicated for pain, we suspected that providers were preferentially choosing specific medications if other indications were present. Therefore, we conducted two stratified analyses (by AUD and by chronic pain) to assess whether results varied by subgroups. We also conducted multiple sensitivity analyses. These are detailed in the <xref rid="SD1" ref-type="supplementary-material">appendix</xref>.</p></sec></sec><sec id="S22"><title>Results</title><sec id="S23"><title>Cohort</title><p id="P27">After applying our exclusion criteria (<xref rid="F1" ref-type="fig">Figure 1</xref>), the study cohort included 11,641 patients: 1,755 initiated XR-NTX and 9,886 initiated SL-BUP. <xref rid="T1" ref-type="table">Table 1</xref> includes the cohort characteristics overall and stratified by medication (<xref rid="SD1" ref-type="supplementary-material">Appendix Table 3</xref> includes standardized mean differences). In general, patients who initiated XR-NTX had a higher prevalence of many health conditions, higher medication use (particularly antidepressants and antipsychotics), and higher healthcare utilization than patients who initiated SL-BUP. Disability and chronic pain were the only conditions that were notably higher among patients who initiated SL-BUP. The median days supply for SL-BUP was 15 (interquartile range [IQR] 11, 30).</p></sec><sec id="S24"><title>Outcomes</title><p id="P28"><xref rid="SD1" ref-type="supplementary-material">Appendix Table 4</xref> includes the number of outcomes identified, person-time of follow-up and the crude event rates. For the composite outcome of discontinuation all MOUD or death, 6,756 (58%) patients had an event by 6 months (including &lt;11 deaths) and 474 (4%) were lost to follow-up. For the composite outcome of overdose or death, 353 (3%) patients had an event (including &lt;11 deaths) and 928 (8%) patients were lost to follow-up.</p></sec><sec id="S25"><title>Primary analysis</title><p id="P29"><xref rid="F2" ref-type="fig">Figure 2</xref> presents the crude and adjusted risk curves (in %) and risk difference (RD) curves (as percentage points) for the composite discontinuation of all MOUD and death. The numeric results at specific time points are presented in <xref rid="T2" ref-type="table">Table 2</xref>. Because XR-NTX treatment duration was 30 days and we used a 31-day grace period, patients who initiated XR-NTX were not at risk of discontinuation until day 61 (week 9). Thus, we see a jump in the risk of discontinuation at week 9 for the XR-NTX group. For SL-BUP, initial medication supply varied so patients were at risk of discontinuation earlier (end of supply + 31 days). Therefore, before week 9, the risk of discontinuation is lower for XR-NTX (RD&lt;0), but after week 9, discontinuation is higher for XR-NTX (RD&gt;0). The adjusted risk of discontinuation by week 26 (end of follow-up) after XR-NTX initiation was 76% (95% CI 75%, 78%); the risk was 62% (95% CI 61%, 63%) after SL-BUP initiation. The adjusted risk difference was 14 percentage points (95% CI 13, 16), i.e., among 100 patients, 14 additional patients are expected to discontinue MOUD or die by 6 months if everyone were treated with XR-NTX compared to if everyone were treated with SL-BUP. Results were similar for the outcome of discontinuation of initial medication (<xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="SD1" ref-type="supplementary-material">Appendix Figure 2</xref>).</p><p id="P30"><xref rid="F3" ref-type="fig">Figure 3</xref> and <xref rid="T2" ref-type="table">Table 2</xref> present results for the composite of overdose and death. In the crude analysis, the risk among patients who initiated XR-NTX began to separate from the risk among patients who initiated SL-BUP around week 13. By the end of follow-up, the crude risk after XR-NTX initiation was 5.1% (95% 4.1%, 6.3%); the crude risk after SL-BUP initiation was 3.1% (95% 2.7%, 3.4%). The crude risk difference was 2.1 percentage points (95% CI 0.06, 3.5) indicating a higher observed risk of overdose after XR-NTX. In the adjusted analysis, however, the risk curves are more similar to each other. The adjusted risk was 3.8% (95% CI 2.9%, 4.7%) after XR-NTX initiation and 3.3% (95% 2.9%, 3.7%) after SL-BUP initiation; the adjusted risk difference was 0.5 percentage points, 95% CI &#8722;0.5, 1.5).</p></sec><sec id="S26"><title>Additional analyses</title><p id="P31"><xref rid="T3" ref-type="table">Table 3</xref> presents the adjusted risk differences by 26 weeks for the additional analyses. We did not observe heterogeneity by AUD or chronic pain in the comparative effect of medication on discontinuation. Results did not vary meaningfully across sensitivity analyses or compared to the primary analysis. For overdose, the largest risk difference observed was 1.1 percentage points (95% CI &#8722;0.7, 2.8).</p></sec></sec><sec id="S27"><title>Discussion</title><p id="P32">Our objective was to compare the real-world effectiveness of XR-NTX and SL-BUP. Such evidence can help inform Medicaid patients and their providers deciding between XR-NTX or SL-BUP for OUD. We found that, consistent with national data,[<xref rid="R32" ref-type="bibr">32</xref>] a majority of patients discontinued medication before 6 months (a minimally adequate duration of treatment[<xref rid="R33" ref-type="bibr">33</xref>]), though the proportion that discontinued was notably higher for XR-NTX than for SL-BUP. Despite this greater early medication discontinuation, there was only a small elevated risk of overdose (&lt;1 percentage point) for XR-NTX after adjustment.</p><p id="P33">Randomized trials comparing these medications have not observed a notable difference in medication retention.[<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>] In contrast, and consistent with our results, a prior analysis of commercially insured patients found the hazard of discontinuation was 2 times higher for XR-NTX compared to SL-BUP.[<xref rid="R15" ref-type="bibr">15</xref>] There are several potential reasons for this discrepancy between trial and real-world data results. First, there are likely differences in the distribution of patient characteristics between the trial and real-world population[<xref rid="R12" ref-type="bibr">12</xref>] and these characteristics may increase or decrease the risk of medication discontinuation. For example, the proportion of people experiencing unstable housing may differ between trial and real-world populations and unstable housing has been shown to effect medication effectiveness.[<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>] Second, there are also differences in how treatment is delivered, including care setting, provider type, and retention incentives, and these differences may impact retention differently for each medication. Trials often have highly structured follow-up with research teams motivated to engage and keep in touch with patients, including reaching out to patients who miss appointments. This level of follow-up is often not available in community-based treatment. Third, the results from trials may be biased by selection. Some trial analyses were restricted to individuals who initiated medication without accounting for bias induced by conditioning on successful initiation.[<xref rid="R34" ref-type="bibr">34</xref>] Such selection bias may favor XR-NTX since the difficult induction (i.e., the need to be opioid abstinent) may select for participants more likely to have better outcomes.</p><p id="P34">Discontinuation of medication for OUD is associated with illicit opioid use, overdose, and other negative outcomes.[<xref rid="R35" ref-type="bibr">35</xref>] Thus, given the observed difference in medication discontinuation, we expected a larger difference in overdose risk. In our study, the crude risk of overdose was higher for XR-NTX than SL-BUP, but this difference was attenuated after adjustment. This attenuation reflects that patients with greater severity of illness and greater prevalence of co-morbidities were more likely to receive XR-NTX than SL-BUP (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p id="P35">Results from one trial, X:BOT, have sparked debate regarding the comparative risk of overdose between XR-NTX and SL-BUP.[<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>] The primary analysis found no significant difference in the proportion of patients with a MEDRA defined overdose.[<xref rid="R7" ref-type="bibr">7</xref>] Follow-up analyses identified additional probable or possible overdose events, in part highlighting the need for more precise measurement of overdose in future trials.[<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>] One analysis found that XR-NTX had two times the hazard of overdose than SL-BUP.[<xref rid="R8" ref-type="bibr">8</xref>] Further analysis suggested that the number of overdoses was similar regardless of medication, but overdoses tended to occur sooner after medication discontinuation for XR-NTX than SL-BUP.[<xref rid="R9" ref-type="bibr">9</xref>] It appears that the overdose risk after XR-NTX treatment was higher in the X:BOT trial (range 4&#8211;6%) than in our study (adjusted 3.8%). In our study, we were only able to capture overdose events that resulted in a Medicaid claim and this likely misses overdoses that occur in the community not resulting in a visit to a healthcare facility; in contrast, the trial had systematic follow-up that has superior capture of overdose events. It is unclear how differences in capture may contribute to these different results. The risk difference was larger in our sensitivity analysis using a more sensitive overdose definition (0.9 versus 0.5 percentage points in our primary analysis) potentially indicating bias towards the null.</p><p id="P36">We found only one study that examined overdose in real-world data and specifically assessed XR-NTX.[<xref rid="R16" ref-type="bibr">16</xref>] This study did not compare XR-NTX and SL-BUP directly but instead compared each medication to no medication. Further, this study assessed MOUD as a time-varying treatment and thus was not focused on comparing medication choice at initiation (as done in our analysis and X:BOT). The authors found that in a population of commercially insured adults both XR-NTX and SL-BUP had hazard ratios less than 1 compared to no medication though SL-BUP hazard ratio was smaller, potentially indicating greater protection against overdose for SL-BUP than for XR-NTX. Both medications have high affinity for opioid receptors and protect against overdose by blocking opioid receptor, however, after discontinuation this protection is lost and patients on XR-NTX may be at higher risk of overdose because of lack of tolerance.</p><p id="P37">To interpret our estimates as valid causal effects, we relied on assumptions (see <xref rid="S10" ref-type="sec">methods</xref>), most notably that there was no residual confounding. We have taken steps, including using a large number of covariates and a doubly robust estimator with machine learning, to make those assumptions more likely to hold. However, there may still be bias, particularly from residual confounding. We used insurance claims records and there may be measurement error. For example, we did not have access to data on the medication dosing instructions and adherence potentially leading to measurement of medication discontinuation. Additionally, these data may not capture all deaths during enrollment and, as mentioned above, these data only capture a subset of overdoses that generate a claim. Finally, we only had access to data from CA and NJ so these results may not be generalizable to Medicaid patients in other States or uninsured or privately insured patients.</p><p id="P38">In addition to our use of a doubly robust estimator with machine learning, our study has other strengths. We estimated adjusted risk curves and differences over time, in contrast to prior work that estimated hazard ratios. Hazard ratios are averages and thus change with the length of follow-up. They do not provide specific information about how risk of the outcome varies over time.[<xref rid="R36" ref-type="bibr">36</xref>] In contrast, adjusted risk curves do not ignore the distribution of outcomes during follow-up. This is particularly important for MOUD as incrementally longer duration of treatment may have benefits even though the majority of patients discontinue by 6 months. Additionally, providers and patients prefer measures of absolute risk and differences for decision making as opposed to relative measures.[<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R38" ref-type="bibr">38</xref>]. Finally, our study used recent Medicaid data. There has been limited research comparing XR-NTX and SL-BUP among Medicaid patients and Medicaid is the largest payer of OUD treatment in the US.[<xref rid="R39" ref-type="bibr">39</xref>]</p></sec><sec id="S28"><title>Conclusion</title><p id="P39">Among Medicaid patients in California and New Jersey, medication retention was longer on SL-BUP than XR-NTX though the risk of overdose was similar. On average, these results support the use of SL-BUP over XR-NTX, however, given the diversity of the population of OUD patients, XR-NTX may the best choice for some patients, particularly those who do not want agonist treatment. Further, a minority of patients stayed on medication for 6-months, highlighting the need for other interventions to improve retention, particularly for patients initiating XR-NTX. More research is needed to identify which patients do best on which medication.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="media-1.pdf" id="d66e494" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S29"><title>Primary funding:</title><p id="P40">NIH NIDA 5R01DA056407</p></ack><fn-group><fn id="FN1" fn-type="COI-statement"><p id="P42">Declarations of competing interest: Dr. Nunes has served as an investigator on NIH-funded studies that received donated medication or digital therapeutics from Alkermes, Braeburn, Camurus, Indivior, Chess Health, and Pear Therapeutics, and has served as a consultant without compensation to Alkermes, Camurus, Indivior, and Pear Therapeutics. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.</p></fn></fn-group><sec sec-type="data-availability" id="S30"><title>Data availability statement:</title><p id="P41">Research data are not shared. The data that support the findings of this study are available from the Research Data Assistance Center. Restrictions apply to the availability of these data, which were used under license for this study. All code and data definitions are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/CI-NYC" ext-link-type="uri">https://github.com/CI-NYC</ext-link></p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><collab>TIP 63: Medications for Opioid Use Disorde</collab>. <source>Tech. rep. Subtance Abuse and Mental Health Services Administration</source>, <year>2021</year><month>Jul</month>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002" ext-link-type="uri">https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002</ext-link></comment> [<date-in-citation>Accessed on: 2023 Oct 2</date-in-citation>]</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><collab>The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. en</collab>. <source>Journal of Addiction Medicine</source><year>2020</year><month>Mar</month>; <volume>14</volume>:<fpage>1</fpage>&#8211;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000633</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000633</pub-id> [<date-in-citation>Accessed on: 2023 Oct 15</date-in-citation>]<pub-id pub-id-type="pmid">32511106</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shover</surname><given-names>CL</given-names></name>. <collab>Commentary on Larance</collab><etal/> . <article-title>(2020): Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine. en</article-title>. <source>Addiction</source><year>2020</year><month>Jul</month>; <volume>115</volume>:<fpage>1306</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1111/add.15048</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1111/add.15048</pub-id> [<date-in-citation>Accessed on: 2023 Oct 4</date-in-citation>]<pub-id pub-id-type="pmid">32304255</pub-id><pub-id pub-id-type="pmcid">PMC8050841</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ross</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Rudolph</surname><given-names>KE</given-names></name>, and <name name-style="western"><surname>Shover</surname><given-names>C</given-names></name>. <article-title>Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018&#8211;2022. en</article-title>. <source>preprint</source>. <year>2024</year><month>Jan</month>. doi: <pub-id pub-id-type="doi">10.1101/2024.01.05.24300895</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1101/2024.01.05.24300895</pub-id> [<date-in-citation>Accessed on: 2024 Jan 15</date-in-citation>]<pub-id pub-id-type="pmcid">PMC12050076</pub-id><pub-id pub-id-type="pmid">39149781</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tanum</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Solli</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Latif</surname><given-names>ZeH</given-names></name>, <name name-style="western"><surname>Benth</surname><given-names>J&#352;</given-names></name>, <name name-style="western"><surname>Opheim</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sharma-Haase</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Krajci</surname><given-names>P</given-names></name>, and <name name-style="western"><surname>Kun&#248;e</surname><given-names>N</given-names></name>. <article-title>Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. en</article-title>. <source>JAMA Psychiatry</source><year>2017</year><month>Dec</month>; <volume>74</volume>:<fpage>1197</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.3206</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.3206</pub-id> [<date-in-citation>Accessed on: 2023 Oct 1</date-in-citation>]<pub-id pub-id-type="pmid">29049469</pub-id><pub-id pub-id-type="pmcid">PMC6583381</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Korthuis</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Lum</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Waddell</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Tookes</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Vergara-Rodriguez</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kunkel</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Lucas</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Bielavitz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fanucchi</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Hoffman</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Bachrach</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oden</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jelstrom</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sorensen</surname><given-names>JL</given-names></name>, and <name name-style="western"><surname>McCarty</surname><given-names>D</given-names></name>. <article-title>HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. en</article-title>. <source>Addiction</source><year>2022</year><month>Jul</month>; <volume>117</volume>:<fpage>1961</fpage>&#8211;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1111/add.15836</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1111/add.15836</pub-id> [<date-in-citation>Accessed on: 2023 Apr 20</date-in-citation>]<pub-id pub-id-type="pmid">35129242</pub-id><pub-id pub-id-type="pmcid">PMC9314106</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Novo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bachrach</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Bhatt</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Farkas</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fishman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gauthier</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hodgkins</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>King</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lindblad</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>May</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Peavy</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Salazar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Schkolnik</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Shmueli-Blumberg</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Stablein</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Subramaniam</surname><given-names>G</given-names></name>, and <name name-style="western"><surname>Rotrosen</surname><given-names>J</given-names></name>. <article-title>Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. en</article-title>. <source>The Lancet</source><year>2018</year><month>Jan</month>; <volume>391</volume>:<fpage>309</fpage>&#8211;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32812-X</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S014067361732812X" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S014067361732812X</ext-link></comment> [<date-in-citation>Accessed on: 2023 Apr 17</date-in-citation>]<pub-id pub-id-type="pmcid">PMC5806119</pub-id><pub-id pub-id-type="pmid">29150198</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ajazi</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Monaco</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Howard</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Preisser</surname><given-names>JS</given-names></name>, and <name name-style="western"><surname>Schwartz</surname><given-names>TA</given-names></name>. <article-title>Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis. en</article-title>. <source>Journal of Addiction Medicine</source><year>2022</year><month>Jul</month>; <volume>16</volume>:<fpage>440</fpage>&#8211;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000931</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000931</pub-id> [<date-in-citation>Accessed on: 2023 Apr 18</date-in-citation>]<pub-id pub-id-type="pmid">35960214</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Novo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>May</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Van Veldhuisen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lindblad</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, and <name name-style="western"><surname>Rotrosen</surname><given-names>J</given-names></name>. <collab>Commentary on Ajazi</collab><etal/><article-title>(2021) Re-analysis of the X:BOT Trial. en</article-title>. <source>Journal of Addiction Medicine</source><year>2022</year><month>Jul</month>; <volume>16</volume>:<fpage>382</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000930</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000930</pub-id> [<date-in-citation>Accessed on: 2023 Apr 24</date-in-citation>]<pub-id pub-id-type="pmid">35960212</pub-id><pub-id pub-id-type="pmcid">PMC9375053</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ajazi</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>TA</given-names></name>, and <name name-style="western"><surname>Marshall</surname><given-names>SW</given-names></name>. <article-title>Misclassification of overdose events in the X:BOT study. en</article-title>. <source>The Lancet</source><year>2023</year><month>Aug</month>; <volume>402</volume>:<fpage>526</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(23)00113-7</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0140673623001137" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0140673623001137</ext-link></comment> [<date-in-citation>Accessed on: 2023 Sep 18</date-in-citation>]<pub-id pub-id-type="pmid">37480936</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Van Veldhuisen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lindblad</surname><given-names>R</given-names></name>, and <name name-style="western"><surname>Rotrosen</surname><given-names>J</given-names></name>. <article-title>Misclassification of overdose events in the X:BOT study &#8211; Authors&#8217; reply. en</article-title>. <source>The Lancet</source><year>2023</year><month>Aug</month>; <volume>402</volume>:<fpage>527</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(23)00049-1</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0140673623000491" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0140673623000491</ext-link></comment> [<date-in-citation>Accessed on: 2023 Sep 18</date-in-citation>]<pub-id pub-id-type="pmid">37480935</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rudolph</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>SX</given-names></name>, <name name-style="western"><surname>Rotrosen</surname><given-names>J</given-names></name>, and <name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name>. <article-title>Under-representation of key demographic groups in opioid use disorder trials. en</article-title>. <source>Drug and Alcohol Dependence Reports</source><year>2022</year><month>Sep</month>; <volume>4</volume>:<fpage>100084</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dadr.2022.100084</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S2772724622000592" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S2772724622000592</ext-link></comment> [<date-in-citation>Accessed on: 2022 Aug 18</date-in-citation>]<pub-id pub-id-type="pmid">36187300</pub-id><pub-id pub-id-type="pmcid">PMC9524855</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rudolph</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>D&#237;az</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>SX</given-names></name>, <name name-style="western"><surname>Rotrosen</surname><given-names>J</given-names></name>, and <name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name>. <article-title>Optimizing opioid use disorder treatment with naltrexone or buprenorphine. en</article-title>. <source>Drug and Alcohol Dependence</source><year>2021</year><month>Nov</month>; <volume>228</volume>:<fpage>109031</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109031</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0376871621005263" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0376871621005263</ext-link></comment> [<date-in-citation>Accessed on: 2022 Nov 20</date-in-citation>]<pub-id pub-id-type="pmid">34534863</pub-id><pub-id pub-id-type="pmcid">PMC8595679</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Scodes</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Pavlicova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Novo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>AN</given-names></name>, and <name name-style="western"><surname>Rotrosen</surname><given-names>J</given-names></name>. <article-title>Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. en</article-title>. <source>American Journal of Psychiatry</source><year>2021</year><month>Jul</month>; <volume>178</volume>:<fpage>660</fpage>&#8211;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.ajp.2020.20060816</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1176/appi.ajp.2020.20060816</pub-id> [<date-in-citation>Accessed on: 2023 Dec 6</date-in-citation>]<pub-id pub-id-type="pmid">34170188</pub-id><pub-id pub-id-type="pmcid">PMC11061873</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Morgan</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Schackman</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Leff</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Linas</surname><given-names>BP</given-names></name>, and <name name-style="western"><surname>Walley</surname><given-names>AY</given-names></name>. <article-title>Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. en</article-title>. <source>Journal of Substance Abuse Treatment</source><year>2018</year><month>Feb</month>; <volume>85</volume>:<fpage>90</fpage>&#8211;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jsat.2017.07.001</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0740547216304135" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0740547216304135</ext-link></comment> [<date-in-citation>Accessed on: 2023 Jul 27</date-in-citation>]<pub-id pub-id-type="pmid">28733097</pub-id><pub-id pub-id-type="pmcid">PMC5750108</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Morgan</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Schackman</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Weinstein</surname><given-names>ZM</given-names></name>, <name name-style="western"><surname>Walley</surname><given-names>AY</given-names></name>, and <name name-style="western"><surname>Linas</surname><given-names>BP</given-names></name>. <article-title>Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort</article-title>. <source>en. Drug and Alcohol Dependence</source><year>2019</year><month>Jul</month>; <volume>200</volume>:<fpage>34</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.02.031</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0376871619301310" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0376871619301310</ext-link></comment> [<date-in-citation>Accessed on: 2023 Sep 18</date-in-citation>]<pub-id pub-id-type="pmcid">PMC6613830</pub-id><pub-id pub-id-type="pmid">31082666</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Friedman</surname><given-names>J</given-names></name> and <name name-style="western"><surname>Shover</surname><given-names>CL</given-names></name>. <article-title>Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010&#8211;2021. en</article-title>. <source>Addiction</source><year>2023</year><month>Dec</month>; <volume>118</volume>:<fpage>2477</fpage>&#8211;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1111/add.16318</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1111/add.16318</pub-id> [<date-in-citation>Accessed on: 2024 Jan 3</date-in-citation>]<pub-id pub-id-type="pmid">37705148</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Bernson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Land</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Xuan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Bagley</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Liebschutz</surname><given-names>JM</given-names></name>, and <name name-style="western"><surname>Walley</surname><given-names>AY</given-names></name>. <article-title>Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. en</article-title>. <source>Annals of Internal Medicine</source><year>2018</year><month>Aug</month>; <volume>169</volume>:<fpage>137</fpage>. doi: <pub-id pub-id-type="doi">10.7326/M17-3107</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.7326/M17-3107</pub-id> [<date-in-citation>Accessed on: 2023 Sep 18</date-in-citation>]<pub-id pub-id-type="pmid">29913516</pub-id><pub-id pub-id-type="pmcid">PMC6387681</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tossone</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ashmead</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bickert</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Doogan</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Mack</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>S</given-names></name>, and <name name-style="western"><surname>Bonny</surname><given-names>AE</given-names></name>. <article-title>Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data. en</article-title>. <source>Journal of Substance Abuse Treatment</source><year>2022</year><month>May</month>; <volume>136</volume>:<fpage>108686</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jsat.2021.108686</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0740547221004128" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0740547221004128</ext-link></comment> [<date-in-citation>Accessed on: 2023 Jun 26</date-in-citation>]<pub-id pub-id-type="pmid">34953637</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lund</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>DB</given-names></name>, and <name name-style="western"><surname>St&#252;rmer</surname><given-names>T</given-names></name>. <article-title>The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application</article-title>. <source>Pharmacoepidemiology and Drug Safety</source><year>2015</year>; <volume>2</volume>:<fpage>221</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40471-015-0053-5</pub-id><pub-id pub-id-type="pmcid">PMC4778958</pub-id><pub-id pub-id-type="pmid">26954351</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, and <name name-style="western"><surname>Leaf</surname><given-names>DE</given-names></name>. <article-title>Target Trial Emulation: A Framework for Causal Inference From Observational Data. en</article-title>. <source>JAMA</source><year>2022</year><month>Dec</month>; <volume>328</volume>:<fpage>2446</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2022.21383</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/2799678" ext-link-type="uri">https://jamanetwork.com/journals/jama/fullarticle/2799678</ext-link></comment> [<date-in-citation>Accessed on: 2022 Dec 27</date-in-citation>]<pub-id pub-id-type="pmid">36508210</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="webpage"><source>Opioid Prescription Data Resources</source>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/opioids/data-resources/index.html" ext-link-type="uri">https://www.cdc.gov/opioids/data-resources/index.html</ext-link></comment> [<date-in-citation>Accessed on: 2023 Jun 27</date-in-citation>]</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="webpage"><source>Opioid Use Disorder (OUD) 1: Overarching Opioid Use Disorder</source>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.ccwdata.org/documents/10280/19140001/oth-cond-algo-oud.pdf" ext-link-type="uri">https://www2.ccwdata.org/documents/10280/19140001/oth-cond-algo-oud.pdf</ext-link></comment> [<date-in-citation>Accessed on: 2023 Jul 7</date-in-citation>]</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="webpage"><collab>Athena Vocabularies Repository</collab>. <source>OHDSI: Observational Health Data Sciences and Informatics</source>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://athena.ohdsi.org/search-terms/start" ext-link-type="uri">https://athena.ohdsi.org/search-terms/start</ext-link></comment> [<date-in-citation>Accessed on: 2023 Jun 15</date-in-citation>]</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Busch</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Kennedy-Hendricks</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schilling</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Hollander</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meiselbach</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Barry</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></name>, and <name name-style="western"><surname>Eisenberg</surname><given-names>MD</given-names></name>. <article-title>Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care. en</article-title>. <source>Medical Care</source><year>2023</year><month>May</month>; <volume>61</volume>:<fpage>314</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MLR.0000000000001838</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1097/MLR.0000000000001838</pub-id> [<date-in-citation>Accessed on: 2023 Jul 14</date-in-citation>]<pub-id pub-id-type="pmid">36917776</pub-id><pub-id pub-id-type="pmcid">PMC10377507</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Suissa</surname><given-names>S.</given-names></name><article-title>Immortal Time Bias in Pharmacoepidemiology. en</article-title>. <source>American Journal of Epidemiology</source><year>2008</year><month>May</month>; <volume>167</volume>:<fpage>492</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1093/aje/kwm324</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1093/aje/kwm324</pub-id><pub-id pub-id-type="pmid">18056625</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Samples</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name>, and <name name-style="western"><surname>Crystal</surname><given-names>S</given-names></name>. <article-title>Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. en</article-title>. <source>Journal of Substance Abuse Treatment</source><year>2018</year><month>Dec</month>; <volume>95</volume>:<fpage>9</fpage>&#8211;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jsat.2018.09.001</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S074054721830134X" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S074054721830134X</ext-link></comment> [<date-in-citation>Accessed on: 2023 Jun 20</date-in-citation>]<pub-id pub-id-type="pmid">30352671</pub-id><pub-id pub-id-type="pmcid">PMC6354252</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vivolo-Kantor</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pasalic</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>PD</given-names></name>, and <name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></name>. <article-title>Defining indicators for drug overdose emergency department visits and hospitalisations in ICD-10-CM coded discharge data. en</article-title>. <source>Injury Prevention</source><year>2021</year><month>Mar</month>; <volume>27</volume>:<fpage>i56</fpage>&#8211;<lpage>i61</lpage>. doi: <pub-id pub-id-type="doi">10.1136/injuryprev-2019-043521</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1136/injuryprev-2019-043521</pub-id> [<date-in-citation>Accessed on: 2023 Oct 17</date-in-citation>]<pub-id pub-id-type="pmid">33674334</pub-id><pub-id pub-id-type="pmcid">PMC7948191</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Williams</surname><given-names>N</given-names></name> and <name name-style="western"><surname>D&#237;az</surname><given-names>I</given-names></name>. <article-title>lmtp: An R Package for Estimating the Causal Effects of Modified Treatment Policies. en</article-title>. <source>Observational Studies</source><year>2023</year>; <volume>9</volume>:<fpage>103</fpage>&#8211;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1353/obs.2023.0019</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://muse.jhu.edu/article/883479" ext-link-type="uri">https://muse.jhu.edu/article/883479</ext-link></comment> [<date-in-citation>Accessed on: 2023 Sep 26</date-in-citation>]</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Van Der Laan</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Polley</surname><given-names>EC</given-names></name>, and <name name-style="western"><surname>Hubbard</surname><given-names>AE</given-names></name>. <article-title>Super Learner. en</article-title>. <source>Statistical Applications in Genetics and Molecular Biology</source><year>2007</year>; <volume>6</volume>:<fpage>Article 25</fpage>. doi: <pub-id pub-id-type="doi">10.2202/1544-6115.1309</pub-id><pub-id pub-id-type="pmid">17910531</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Daniel</surname><given-names>RM</given-names></name>. <part-title>Double Robustness. en</part-title>. <source>Wiley StatsRef: Statistics Reference Online</source>. Ed. by <name name-style="western"><surname>Balakrishnan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Colton</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Everitt</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Piegorsch</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ruggeri</surname><given-names>F</given-names></name>, and <name name-style="western"><surname>Teugels</surname><given-names>JL</given-names></name>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>, <year>2018</year><month>May</month> :<fpage>1</fpage>&#8211;<lpage>14</lpage>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1002/9781118445112.stat08068</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="webpage"><source>Pharmacotherapy for Opioid Use Disorder (POD)</source>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncqa.org/hedis/measures/pharmacotherapy-for-opioid-use-disorder/" ext-link-type="uri">https://www.ncqa.org/hedis/measures/pharmacotherapy-for-opioid-use-disorder/</ext-link></comment> [<date-in-citation>Accessed on: 2024 Jan 10</date-in-citation>]</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><source>Quality ID #468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)</source>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_468_MIPSCQM.pdf" ext-link-type="uri">https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_468_MIPSCQM.pdf</ext-link></comment> [<date-in-citation>Accessed on: 2023 Oct 17</date-in-citation>]</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name> and <name name-style="western"><surname>Hern&#225;ndez-D&#237;az</surname><given-names>S</given-names></name>. <article-title>Beyond the intention-to-treat in comparative effectiveness research</article-title>. <source>en. Clinical Trials: Journal of the Society for Clinical Trials</source><year>2012</year><month>May</month>; <volume>9</volume>:<fpage>48</fpage>&#8211;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1740774511420743</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1177/1740774511420743</pub-id><pub-id pub-id-type="pmcid">PMC3731071</pub-id><pub-id pub-id-type="pmid">21948059</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mojtabai</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Fingerhood</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Agus</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lyons</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Weiner</surname><given-names>JP</given-names></name>, and <name name-style="western"><surname>Saloner</surname><given-names>B</given-names></name>. <article-title>Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. en</article-title>. <source>Addiction</source><year>2020</year><month>Sep</month>; <volume>115</volume>:<fpage>1683</fpage>&#8211;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1111/add.14991</pub-id>. <comment>Available from</comment>: <pub-id pub-id-type="doi">10.1111/add.14991</pub-id> [<date-in-citation>Accessed on: 2023 Nov 30</date-in-citation>]<pub-id pub-id-type="pmid">32096302</pub-id><pub-id pub-id-type="pmcid">PMC7426244</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name>. <article-title>The Hazards of Hazard Ratios. en</article-title>. <source>Epidemiology</source><year>2010</year><month>May</month>; <volume>21</volume>:<fpage>13</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181c1ea43</pub-id>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://insights.ovid.com/crossref?an=00001648-201001000-00004" ext-link-type="uri">https://insights.ovid.com/crossref?an=00001648-201001000-00004</ext-link></comment><pub-id pub-id-type="pmid">20010207</pub-id><pub-id pub-id-type="pmcid">PMC3653612</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Murray</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Caniglia</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Swanson</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Hern&#225;ndez-D&#237;az</surname><given-names>S</given-names></name>, and <name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name>. <article-title>Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials</article-title>. <source>Journal of Clinical Epidemiology</source><year>2018</year>; <volume>103</volume>:<fpage>10</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jclinepi.2018.06.009</pub-id><pub-id pub-id-type="pmid">29966732</pub-id><pub-id pub-id-type="pmcid">PMC6175611</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Freeman</surname><given-names>AL</given-names></name> and <name name-style="western"><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>. <part-title>Communicating health risks in science publications: Time for everyone to take responsibility</part-title>. <source>BMC Medicine</source><year>2018</year>; <volume>16</volume>. <publisher-name>Publisher: BMC Medicine</publisher-name>:<fpage>5</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-018-1194-4</pub-id><pub-id pub-id-type="pmid">30419964</pub-id><pub-id pub-id-type="pmcid">PMC6233494</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="webpage"><source>Medicaid&#8217;s Role in Addressing the Opioid Epidemic</source>. <comment>Available from</comment>: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/" ext-link-type="uri">https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/</ext-link></comment> [<date-in-citation>Accessed on: 2023 Dec 12</date-in-citation>]</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p id="P43">Flowchart of cohort creation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2024.01.24.24301555v2-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p id="P44">Analysis results for composite of discontinuation of all MOUD and death: A. Crude risk. B. Adjusted risk. C. Adjusted risk difference. Shaded areas are 95% confidence intervals. Abbreviations: MOUD, medications for opioid use disorder; XR-NTX, extended release naltrexone; SL-BUP, sublingual buprenorphine</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2024.01.24.24301555v2-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p id="P45">Analysis results for composite of overdose and death: A. Crude risk. B. Adjusted risk. C. Adjusted risk difference. Shaded areas are 95% confidence intervals. Abbreviations: XR-NTX, extended release naltrexone; SL-BUP, sublingual buprenorphine</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2024.01.24.24301555v2-f0003.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p id="P46">Baseline characteristics of study cohort, overall and stratified by medication</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="bottom" rowspan="1">N(%)<hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="top" rowspan="1">Medication<hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">XR-NTX N = 1755</th><th align="center" valign="bottom" rowspan="1" colspan="1">SL-BUP N = 9886</th><th align="center" valign="bottom" rowspan="1" colspan="1">Overall N = 11641</th></tr><tr><th colspan="4" align="left" valign="bottom" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">Demographics</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Age<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">33 (28, 42)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (29, 46)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (29, 45)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Male</td><td align="center" valign="top" rowspan="1" colspan="1">1,015 (58%)</td><td align="center" valign="top" rowspan="1" colspan="1">5,460 (55%)</td><td align="center" valign="top" rowspan="1" colspan="1">6,475 (56%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Race/ethnicity</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;White, non-Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">1,130 (69%)</td><td align="center" valign="top" rowspan="1" colspan="1">6,561 (71%)</td><td align="center" valign="top" rowspan="1" colspan="1">7,691 (70%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Black, non-Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">139 (8.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">835 (9.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">974 (8.9%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Hispanic, all races</td><td align="center" valign="top" rowspan="1" colspan="1">332 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,587 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,919 (18%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Asian, non-Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">24 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">130 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">154 (1.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;AIAN, non-Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">161 (1.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">177 (1.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Hawaiian/Pacific Islander</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">18 (0.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (0.2%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">112</td><td align="center" valign="top" rowspan="1" colspan="1">594</td><td align="center" valign="top" rowspan="1" colspan="1">706</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;TANF benefits</td><td align="center" valign="top" rowspan="1" colspan="1">28 (1.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">334 (3.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">362 (3.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;State</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;California</td><td align="center" valign="top" rowspan="1" colspan="1">908 (52%)</td><td align="center" valign="top" rowspan="1" colspan="1">7,767 (79%)</td><td align="center" valign="top" rowspan="1" colspan="1">8,675 (75%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;New Jersey</td><td align="center" valign="top" rowspan="1" colspan="1">847 (48%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,119 (21%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,966 (25%)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">OUD characteristics</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Inpatient hospitalization<sup><xref rid="TFN3" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">273 (16%)</td><td align="center" valign="top" rowspan="1" colspan="1">465 (4.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">738 (6.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Psychosocial/behavioral therapy</td><td align="center" valign="top" rowspan="1" colspan="1">942 (54%)</td><td align="center" valign="top" rowspan="1" colspan="1">3,352 (34%)</td><td align="center" valign="top" rowspan="1" colspan="1">4,294 (37%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Overdose</td><td align="center" valign="top" rowspan="1" colspan="1">197 (11%)</td><td align="center" valign="top" rowspan="1" colspan="1">742 (7.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">939 (8.1%)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Other substance use disorders</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Alcohol</td><td align="center" valign="top" rowspan="1" colspan="1">686 (39%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,030 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,716 (15%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cannabis</td><td align="center" valign="top" rowspan="1" colspan="1">194 (11%)</td><td align="center" valign="top" rowspan="1" colspan="1">507 (5.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">701 (6.0%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Sedatives</td><td align="center" valign="top" rowspan="1" colspan="1">181 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">491 (5.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">672 (5.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cocaine</td><td align="center" valign="top" rowspan="1" colspan="1">183 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">360 (3.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">543 (4.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Amphetamine</td><td align="center" valign="top" rowspan="1" colspan="1">297 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,403 (14%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,700 (15%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Other<sup><xref rid="TFN4" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">502 (29%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,013 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,515 (22%)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Psychiatric comorbid conditions</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Depression</td><td align="center" valign="top" rowspan="1" colspan="1">634 (36%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,284 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,918 (25%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Schizophrenia/psychosis</td><td align="center" valign="top" rowspan="1" colspan="1">191 (11%)</td><td align="center" valign="top" rowspan="1" colspan="1">613 (6.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">804 (6.9%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Anxiety</td><td align="center" valign="top" rowspan="1" colspan="1">611 (35%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,635 (27%)</td><td align="center" valign="top" rowspan="1" colspan="1">3,246 (28%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Bipolar</td><td align="center" valign="top" rowspan="1" colspan="1">269 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">967 (9.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,236 (11%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;ADD/ADHD</td><td align="center" valign="top" rowspan="1" colspan="1">67 (3.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">254 (2.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">321 (2.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;PTSD</td><td align="center" valign="top" rowspan="1" colspan="1">162 (9.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">643 (6.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">805 (6.9%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Other</td><td align="center" valign="top" rowspan="1" colspan="1">301 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,234 (12%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,535 (13%)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="4" align="left" valign="middle" rowspan="1">Other comorbid conditions</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Disability<sup><xref rid="TFN5" ref-type="table-fn">d</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">102 (5.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,450 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,552 (13%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Chronic pain</td><td align="center" valign="top" rowspan="1" colspan="1">183 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,228 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,411 (21%)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Medications</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Benzodiazepines</td><td align="center" valign="top" rowspan="1" colspan="1">518 (30%)</td><td align="center" valign="top" rowspan="1" colspan="1">3,064 (31%)</td><td align="center" valign="top" rowspan="1" colspan="1">3,582 (31%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Antidepressants</td><td align="center" valign="top" rowspan="1" colspan="1">1,018 (58%)</td><td align="center" valign="top" rowspan="1" colspan="1">4,152 (42%)</td><td align="center" valign="top" rowspan="1" colspan="1">5,170 (44%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Antipsychotics</td><td align="center" valign="top" rowspan="1" colspan="1">550 (31%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,903 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,453 (21%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Stimulants</td><td align="center" valign="top" rowspan="1" colspan="1">64 (3.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">351 (3.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">415 (3.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Gabapentinoids</td><td align="center" valign="top" rowspan="1" colspan="1">575 (33%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,563 (26%)</td><td align="center" valign="top" rowspan="1" colspan="1">3,138 (27%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Alpha-2 agonists</td><td align="center" valign="top" rowspan="1" colspan="1">304 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,762 (18%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,066 (18%)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="4" align="left" valign="middle" rowspan="1">Healthcare utilization</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Inpatient hospitalization</td><td align="center" valign="top" rowspan="1" colspan="1">590 (34%)</td><td align="center" valign="top" rowspan="1" colspan="1">1,916 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">2,506 (22%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Emergency department encounter</td><td align="center" valign="top" rowspan="1" colspan="1">1,168 (67%)</td><td align="center" valign="top" rowspan="1" colspan="1">5,830 (59%)</td><td align="center" valign="top" rowspan="1" colspan="1">6,998 (60%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Other services encounters, count<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">23 (7, 56)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3, 28)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (3, 31)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P47">Abbreviations: XR-NTX, extended release naltrexone; SL-BUP, sublingual buprenorphine; AIAN, American Indian or Alaskan Native; TANF, Temporary Assistance for Needy Families; OUD, opioid use disorder; ADD/ADHD, attention-deficit disorder/attention deficit hyperactivity disorder; PTSD, post-traumatic stress disorder</p></fn><fn id="TFN2"><label>a</label><p id="P48">Median (interquartile range)</p></fn><fn id="TFN3"><label>b</label><p id="P49">With primary diagnosis code of opioid dependence or overdose</p></fn><fn id="TFN4"><label>c</label><p id="P50">Excluding nicotine</p></fn><fn id="TFN5"><label>d</label><p id="P51">Reason for eligibility for Medicaid insurance</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>Table 2.</label><caption><p id="P52">Primary analysis results: crude and adjusted risks (as %) and risk differences (in percentage points)</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="middle" rowspan="1">Crude (95% CI)<hr/></th><th colspan="3" align="center" valign="middle" rowspan="1">Adjusted (95% CI)<hr/></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">Risks<hr/></th><th align="left" valign="middle" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">Risks<hr/></th><th align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Week</th><th align="center" valign="middle" rowspan="1" colspan="1">XR-NTX</th><th align="center" valign="middle" rowspan="1" colspan="1">SL-BUP</th><th align="center" valign="middle" rowspan="1" colspan="1">Difference</th><th align="center" valign="middle" rowspan="1" colspan="1">XR-NTX</th><th align="center" valign="middle" rowspan="1" colspan="1">SL-BUP</th><th align="center" valign="middle" rowspan="1" colspan="1">Difference</th></tr><tr><th colspan="7" align="left" valign="middle" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td colspan="7" align="left" valign="middle" rowspan="1">Discontinuation of all MOUD or death</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">
<hr/>
</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">36.1 (33.8, 38.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">31.0 (30.1, 32)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1 (1.9, 8.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.7 (31.9, 35.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">30.7 (29.7, 31.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 (1.0, 5.0)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">45.1 (42.7, 47.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.7 (41.6, 43.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5 (&#8722;1.0, 5.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">43.0 (40.5, 45.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.4 (41.4, 43.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 (&#8722;2.2, 3.3)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">60.0 (57.6, 62.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">53.0 (51.9, 54.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.0 (3.6, 10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">59.3 (56.9, 61.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">53.0 (52.0, 54.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3 (3.6, 8.9)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">69.5 (67.3, 71.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">58.0 (56.9, 59.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6 (8.3, 14.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">69.7 (67.5, 71.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">58.1 (57.1, 59.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.5 (9.1, 14.0)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">75.1 (72.9, 77.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">61.8 (60.8, 62.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.3 (10.1, 16.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">76.4 (75.1, 77.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">62.2 (61.2, 63.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.1 (12.5, 15.7)</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">
<hr/>
</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">Discontinuation of initial medication or death</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">
<hr/>
</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">37.6 (35.3, 40.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">32.9 (31.9, 33.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.7 (1.4, 8.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">34.4 (31.9, 36.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">32.7 (31.7, 33.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8 (&#8722;0.9, 4.4)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">47.0 (44.6, 49.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.7 (43.7, 45.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3 (&#8722;1.2, 5.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.7 (42.2, 47.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.6 (43.6, 45.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 (&#8722;2.6, 2.8)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">62.4 (60.0, 64.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">55.0 (54.0, 56.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.4 (4.0, 10.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">62.0 (60.5, 63.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">55.2 (54.1, 56.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9 (5.0, 8.7)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">71.7 (69.4, 73.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.1 (59.1, 61.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.5 (8.3, 14.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">72.8 (71.5, 74.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.4 (59.4, 61.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 (10.7, 14.1)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">77.3 (75.2, 79.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">63.8 (62.8, 64.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.5 (10.4, 16.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">79.4 (78.2, 80.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">64.4 (63.4, 65.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.0 (13.5, 16.6)</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">
<hr/>
</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">Overdose or death</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1">
<hr/>
</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2 (0.8, 1.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 (0.9, 1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 (&#8722;0.6, 0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 (0.8, 1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2 (1.0, 1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.1 (&#8722;0.5, 0.3)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3 (1.7, 3.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7 (1.5, 2.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 (&#8722;0.4, 1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.9 (1.5, 2.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.9 (1.6, 2.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (&#8722;0.5, 0.5)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6 (2.8, 4.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3 (2.0, 2.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2 (0.0, 2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.7 (2.2, 3.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5 (2.2, 2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2 (&#8722;0.4, 0.8)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9 (3.9, 6.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8 (2.4, 3.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1 (0.7, 3.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.7 (3.2, 4.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 (2.6, 3.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.1, 1.4)</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1 (4.1, 6.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1 (2.7, 3.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1 (0.6, 3.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.8 (2.9, 4.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3 (2.9, 3.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 (&#8722;0.5, 1.5)</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p id="P53">Abbreviations: XR-NTX, extended release naltrexone; SL-BUP, sublingual buprenorphine; MOUD, medications for opioid use disorder</p></fn><fn id="TFN7"><label>a</label><p id="P54">Week 9: days 57&#8211;63; week 13: days 85&#8211;91; week 18: days 120&#8211;126; week 22: days 148&#8211;154; week 26: days 176&#8211;180</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p id="P55">Additional analyses results: risk difference (in percentage points, with 95% confidence interval) at the end of follow-up comparing XR-NTX and SL-BUP</p></caption><table frame="below" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td colspan="2" align="left" valign="top" rowspan="1">Stratified analyses, outcome: discontinuation of all MOUD or death<sup><xref rid="TFN8" ref-type="table-fn">a</xref></sup></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Alcohol use disorder, yes</td><td align="center" valign="top" rowspan="1" colspan="1">14.9 (10.3, 19.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Alcohol use disorder, no</td><td align="center" valign="top" rowspan="1" colspan="1">15.1 (l3.5, 16.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Chronic pain, yes</td><td align="center" valign="top" rowspan="1" colspan="1">11.2 (6.8, 15.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Chronic pain, no</td><td align="center" valign="top" rowspan="1" colspan="1">13.7 (11.9, 15.4)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Sensitivity analyses<sup><xref rid="TFN9" ref-type="table-fn">b</xref></sup></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">&#8195;Outcome: discontinuation of all MOUD or death</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;ATE</td><td align="center" valign="top" rowspan="1" colspan="1">12.8 (9.8, 15.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Among XR-NTX treated</td><td align="center" valign="top" rowspan="1" colspan="1">12.9 (10.2, 15.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Among SL-BUP treated</td><td align="center" valign="top" rowspan="1" colspan="1">13.0 (9.6, 16.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;In optimally trimmed cohort<sup><xref rid="TFN10" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">12.9 (10.3, 15.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Include LTFU in outcome</td><td align="center" valign="top" rowspan="1" colspan="1">12.2 (9.2, 15.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;14-day grace period</td><td align="center" valign="top" rowspan="1" colspan="1">10.4 (7.7, 13.0)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">&#8195;Outcome: overdose or death</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;ATE</td><td align="center" valign="top" rowspan="1" colspan="1">0.5 (&#8722;0.8, 1.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Among XR-NTX treated</td><td align="center" valign="top" rowspan="1" colspan="1">1.1 (&#8722;0.7, 2.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Among SL-BUP treated</td><td align="center" valign="top" rowspan="1" colspan="1">0.5 (&#8722;0.1, 2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;In optimally trimmed cohort<sup><xref rid="TFN10" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">1.1 (&#8722;0.6, 2.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;More sensitive definition<sup><xref rid="TFN9" ref-type="table-fn">b</xref>,<xref rid="TFN11" ref-type="table-fn">d</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.9 (&#8722;0.6, 2.4)</td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><label>a</label><p id="P56">Using survival analysis methods</p></fn><fn id="TFN9"><label>b</label><p id="P57">Analysis at the end of follow-up (not using survival analysis methods)</p></fn><fn id="TFN10"><label>c</label><p id="P58">After trimming, n=6,924 (XR-NTX n=1725, SL-BUP n=5199)</p></fn><fn id="TFN11"><label>d</label><p id="P59">After exclusion of early overdose events with new definition, n=11,630 (XR-NTX n=1752, SL-BUP n=9878)</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>